Posts tagged market perform rating
Leerink starts Endologix at market perform

Leerink Partners initiated coverage of Endologix (NASDAQ:ELGX) with a “market perform” rating and $13 price target. The stock closed at $12.22 on Friday.

Endologix is the largest abdominal aortic aneurysm (AAA) pure play and holds the No. 4 position in the $1.5-billion worldwide AAA market.

Read More
Leerink downgrades Mirna to market perform

Leerink Partners downgraded Mirna Therapeutics (NASDAQ:MIRN) to “market perform” from “outperform” and lowered its price target to $4 from $10, citing added uncertainties around the development path and safety profile of lead product candidate, MRX34. The stock closed at $3.95 on Tuesday.

“While microRNAs represent an intriguing emerging new class of therapeutic targets, recent company updates render us more cautious on the prospects for Mirna shares,” writes analyst Michael Schmidt.

Read More
Leerink upgrades Intellia Therapeutics to outperform

Leerink Partners upgraded Intellia Therapeutics (NASDAQ:NTLA) to “outperform” from “market perform” on valuation, with a price target of $32. The stock closed at $17.66 on Thursday.

“We believe the current valuation, close to the mid-point of the IPO range of $16-$18, represents an attractive entry point to own one of the most exciting technology platforms biotech has to offer,” writes analyst Michael Schmidt.

Read More
Leerink downgrades Trovagene to market perform

Leerink Partners has downgraded Trovagene (NASDAQ:TROV) to “market perform” from “outperform” and lowered its price target to $4.50 from $8, following the recent removal/departure of key senior management. The stock closed at $4.73 on Monday.

“While we remain intrigued by Trovagene’s opportunity in liquid biopsy, a large part of our investment thesis rested on the odds that Trovagene’s leadership could successfully execute on this opportunity,” writes analyst Dan Leonard. “We believe the announced leadership transitions could prove disruptive.”

Read More